Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan-Reference-Cited by-同舟云学术

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan

Published:2023-01-02 Issue:1 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Terada-Hirashima Junko¹²^ORCID,Takamatsu Yuki³,Shimizu Yosuke⁴,Uemura Yukari⁴,Takeuchi Junko S.⁵,Tomita Noriko¹,Matsuda Kouki³,Maeda Kenji³,Yamamoto Shohei⁶,Fukunaga Ami⁶,Ohmagari Norio⁷,Mikami Ayako¹,Sonoda Kengo⁸,Ujiie Mugen⁷,Mitsuya Hiroaki³,Sugiura Wataru⁹

Affiliation:

1. Department of Clinical Research Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

2. Department of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan

3. Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Shinjuku-ku, Tokyo, Japan

4. Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

5. Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

6. Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

7. Disease Control and Prevention Center, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan

8. Development Department, KM Biologics Co. Ltd, Kumamoto, Japan

9. Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

Funder

KM Biologics Kabushiki Kaisha

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2193074

Reference43 articles.

1. Fight against COVID-19 but avoid disruption of services for other communicable diseases (CDs) and noncommunicable diseases (NCDs)

2. R&D Blue Print Team World Health Organization. COVID-19 vaccine tracker and landscape. Website Operator; 2022 Aug 23 [accessed 2022 Aug 25]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

3. SARS-CoV-2 vaccines in development

4. Epidemiology and prevention of vaccine-preventable diseases. The pink book: course textbook 14th edition. 2021 Washington DC: Public Health Foundation Centers for Disease Control and Prevention; [accessed 2022 Nov 10]. https://www.cdc.gov/vaccines/pubs/pinkbook/index.html.

5. Immunity to SARS‐CoV‐2 induced by infection or vaccination

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-arm clinical trials: design, ethics, principles;BMJ Supportive & Palliative Care;2024-06-04